<?xml version="1.0" encoding="UTF-8"?>
<p id="par0135">Recently these drugs have attracted intense attention as a possible solver of COVID-19. Based on Chinese clinical trials [
 <xref rid="bib0340" ref-type="bibr">[68]</xref>, 
 <xref rid="bib0345" ref-type="bibr">[69]</xref>, 
 <xref rid="bib0350" ref-type="bibr">[70]</xref>], a French study evaluated 26 patients treated with hydroxychloroquine and 16 control patients, all positive for the virus at baseline. Despite the small sample size, it showed a reduction or disappearance of the viral load in COVID -19 patients. It also showed that the effect of the drug was enhanced by azithromycin [
 <xref rid="bib0355" ref-type="bibr">71</xref>]. The experimental protocol included 200 mg of oral hydroxychloroquine sulfate, three times a day for ten days in combination with an antibiotic based on clinical judgment. The authors documented the efficacy of hydroxychloroquine in reducing the viral load at day 7. Although the use of HCQ is now approved in many autoimmune and inflammatory systemic diseases, and in oncology, and although it has also been shown that the use of HQC reduces the level of low-density lipoproteins with antithrombotic effect [
 <xref rid="bib0360" ref-type="bibr">72</xref>], cardiac complications are described and related to the accumulation of granular deposits in the cytoplasm, a consequence of lysosomal dysfunction, are described [
 <xref rid="bib0365" ref-type="bibr">73</xref>,
 <xref rid="bib0370" ref-type="bibr">74</xref>].
</p>
